login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
APREA THERAPEUTICS INC (APRE) Stock News
NASDAQ:APRE - Nasdaq -
US03836J2015
-
Common Stock
- Currency: USD
1.88
-0.01 (-0.53%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
APRE Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Benzinga
- Mentions:
CYH
ABP
CASI
VKTX
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
a month ago - By: Aprea Therapeutics
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
a month ago - By: Aprea Therapeutics
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
3 months ago - By: Aprea Therapeutics
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
a year ago - By: BusinessInsider
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
3 months ago - By: Aprea Therapeutics
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
4 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
4 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
4 months ago - By: Benzinga
- Mentions:
CORT
SNWV
INNV
PAVM
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 months ago - By: Aprea Therapeutics
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
4 months ago - By: Aprea Therapeutics
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
5 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
5 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
6 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
6 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
8 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
8 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
9 months ago - By: Aprea Therapeutics
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
9 months ago - By: Aprea Therapeutics
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
9 months ago - By: Aprea Therapeutics
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
9 months ago - By: Aprea Therapeutics
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
10 months ago - By: Aprea Therapeutics
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
10 months ago - By: Aprea Therapeutics
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
10 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
10 months ago - By: Aprea Therapeutics
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
10 months ago - By: Aprea Therapeutics
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
10 months ago - By: Aprea Therapeutics
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
10 months ago - By: Aprea Therapeutics
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
10 months ago - By: Virtual Investor Conferences
- Mentions:
NYSE
ACST
AEMD
UNCY
...
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
11 months ago - By: Virtual Investor Conferences
- Mentions:
VNRX
CHRO
PLX
ACST
...
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
11 months ago - By: Virtual Investor Conferences
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
a year ago - By: Aprea Therapeutics
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
a year ago - By: Aprea Therapeutics
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
a year ago - By: Aprea Therapeutics
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
a year ago - By: Aprea Therapeutics
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
a year ago - By: Aprea Therapeutics
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
a year ago - By: Aprea Therapeutics
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
a year ago - By: InvestorPlace
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
a year ago - By: Aprea Therapeutics
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Please enable JavaScript to continue using this application.